<DOC>
	<DOC>NCT02930109</DOC>
	<brief_summary>A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.</brief_summary>
	<brief_title>A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia</brief_title>
	<detailed_description>Study design: Phase I/II study The Phase I study is open-label with four increasing dose levels for up to four 21-day cycles. Safety and activity will be evaluated at the end of each cycle. The Phase II study is open label with administration of the recommended phase dose of PTX-200 for up to four 21-day cycles. PTX-200 will be co-administered with cytarabine in both the Phase I and Phase II parts of the study.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Pathologic confirmation of the diagnosis of AML, ALL (acute lymphoblastic leukemia), or blastphase CML (chronic myelogenous leukemia) Age ≥ 18 years ECOG Performance Status 02 Patients must be able to give adequate informed consent Hyperleukocytosis with ≥ 30,000 leukemic blasts/µL blood (hydroxyurea permitted up to 24 hours prior to beginning study drugs) Uncontrolled Disseminated Intravascular Coagulation (DIC) Uncontrolled diabetes mellitus Active, uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>